Spiriva: Long-Term Control for COPD Symptom Relief
| Product dosage: 18 mcg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $3.00 | $90.12 (0%) | 🛒 Add to cart |
| 60 | $2.40 | $180.24 $144.19 (20%) | 🛒 Add to cart |
| 120 | $2.18 | $360.49 $261.35 (27%) | 🛒 Add to cart |
| 180 | $2.12 | $540.73 $381.51 (29%) | 🛒 Add to cart |
| 270 | $1.74
Best per cap | $811.09 $470.63 (42%) | 🛒 Add to cart |
Synonyms | |||
Spiriva (tiotropium bromide) is a long-acting muscarinic antagonist (LAMA) inhaler prescribed for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not indicated for the initial relief of acute bronchospasm. By targeting airway smooth muscle, Spiriva provides sustained bronchodilation, helping to improve lung function, reduce exacerbations, and enhance overall quality of life in patients with obstructive airway diseases. Its once-daily dosing supports adherence and consistent symptom control.
Features
- Contains tiotropium bromide as the active pharmaceutical ingredient
- Available as a dry powder inhaler (Spiriva HandiHaler) or soft mist inhaler (Spiriva Respimat)
- Long-acting bronchodilator with 24-hour duration of action
- Designed for once-daily administration
- Metered-dose delivery ensures consistent dosing
- Portable and user-friendly device designs
Benefits
- Improves lung function (FEV₁) within 30 minutes of inhalation, with effects sustained over 24 hours
- Reduces the frequency of COPD exacerbations and associated hospitalizations
- Helps alleviate dyspnea (shortness of breath) and improves exercise tolerance
- Enhances health-related quality of life through better symptom control
- Supports long-term disease management with a convenient once-daily regimen
- May reduce the need for rescue inhalers
Common use
Spiriva is indicated for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). It is used in patients with a confirmed diagnosis of COPD, including those with chronic bronchitis and/or emphysema, to help control symptoms, improve lung function, and reduce the frequency of exacerbations. It is not intended for use as a rescue medication during acute episodes.
Dosage and direction
The recommended dose for Spiriva HandiHaler is the inhalation of the contents of one capsule (containing 18 mcg of tiotropium) once daily, using the HandiHaler device. For Spiriva Respimat, the usual dose is two puffs (2.5 mcg each, total 5 mcg) once daily. Administration should occur at the same time each day. Patients must be instructed on proper inhaler technique to ensure optimal drug delivery to the lungs. The capsule should not be swallowed, and the Respimat cartridge should be primised before first use. Do not exceed the prescribed dose.
Precautions
Spiriva should be used with caution in patients with narrow-angle glaucoma, urinary retention, or renal impairment. Immediate medical attention should be sought if signs of acute narrow-angle glaucoma (eye pain, blurred vision, visual halos) or urinary retention develop. Patients with a history of hypersensitivity reactions to atropine or its derivatives should avoid Spiriva. It is not recommended for use in patients with severe renal impairment (CrCl ≤ 30 mL/min). Caution is advised when co-administering with other anticholinergic medications.
Contraindications
Spiriva is contraindicated in patients with a known hypersensitivity to tiotropium bromide, atropine, or its derivatives, such as ipratropium. It should not be used in patients with a history of hypersensitivity to any component of the formulation. Spiriva is not indicated for the treatment of acute bronchospasm and must not be used as a rescue inhaler.
Possible side effect
Common side effects may include dry mouth, constipation, dyspepsia, upper respiratory tract infection, sinusitis, pharyngitis, and non-specific chest pain. Less frequently, patients may experience urinary retention, blurred vision, glaucoma, tachycardia, palpitations, and paradoxical bronchospasm. Allergic reactions such as skin rash, itching, and angioedema may occur. If severe side effects or signs of hypersensitivity develop, discontinue use and seek medical attention.
Drug interaction
Concurrent use of other anticholinergic-containing medications (e.g., ipratropium, aclidinium) may potentiate adverse effects and is not recommended. Spiriva may interact with drugs that are excreted renally or affect renal function. Use with caution alongside beta-adrenergic agonists, methylxanthines, and corticosteroids, though no clinically significant pharmacokinetic interactions have been consistently observed. Always inform the prescribing physician of all concomitant medications.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped. Do not double the dose to make up for a missed one. Resume the regular dosing schedule the following day.
Overdose
Overdose may lead to anticholinergic symptoms such as dry mouth, visual disturbances, tachycardia, urinary retention, and constipation. In severe cases, delirium, psychosis, or cardiac arrhythmias may occur. Treatment is supportive and symptomatic. There is no specific antidote. Medical attention should be sought immediately in suspected cases of overdose.
Storage
Store at room temperature (15–30°C or 59–86°F) in a dry place. Keep the HandiHaler capsules in the blister pack and remove only immediately before use. For Spiriva Respimat, keep the cartridge in the inhaler and store with the cap on. Protect from moisture and direct light. Keep out of reach of children and pets. Do not puncture or incinerate the container.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication regimen. Individual patient needs and responses may vary.
Reviews
Clinical studies and patient reports consistently highlight Spiriva’s efficacy in improving lung function, reducing exacerbation rates, and enhancing quality of life in COPD patients. Many users note significant relief from chronic breathlessness and reduced reliance on rescue medications. Some report initial dry mouth or throat irritation, which often subsides with continued use. Adherence to proper inhaler technique is frequently emphasized for optimal results.